Pharma interview prep when AI drafts the evidence brief

Check the evidence, plan the review and name who owns the next decision.

What companies say they’re looking for

01 Check the draft against its source

“We document the rationale, we're explicit about how much weight we gave the AI output versus other evidence, and we make an informed judgment.” (opens the source)

Matt Truppo, Global Head of Computational and AI Strategy R&D, Sanofi · Sanofi, Nov 9, 2026

Truppo describes how Sanofi weighs an AI-generated insight against other evidence. Check the draft and source register before you brief the committee.

Development operations analyst interviewCan you use the AI evidence brief?Example

02 Recheck the portfolio inputs

“We’re leveraging AI to improve the quality of all inputs at the decision-making stages for each decision.” (opens the source)

Helen Merianos, SVP, Global Head of R&D Strategy & Portfolio Management, Sanofi · Sanofi, Feb 24, 2026

Merianos describes AI inputs to Sanofi’s portfolio discussions. Check what changes when a programme misses its required review.

Portfolio operations analyst interviewWhich two programme reviews can fit?Example

03 Plan the cross-functional handoff

“Develop and maintain project plans that align formulation, manufacturing, and supply activities with overall program objectives and timelines.” (opens the source)

Novartis, Formulation Project Leader posting · Basel, Switzerland · Novartis Careers, Oct 30, 2026

This Basel posting names planning across formulation, manufacturing and supply. Practise giving an internal meeting owner the revised date and the remaining reviews.

Development programme coordinator interviewCan the reviewed pack make the meeting?Example

04 Say what the cutoff supports

“longer follow-up will be needed to further characterise the durability of response.” (opens the source)

GSK, Company study update · issued in London, UK · GSK, Oct 18, 2026

GSK names a follow-up limit in an early-stage study update. For a fictional cutoff, distinguish verified outcomes from unresolved records.

Development evidence coordinator interviewWhat should the study update say?Example

05 Name the qualified safety owner

“the review of safety data and related documents for potential safety issues in collaboration with the Global Safety Physician (GSP)” (opens the source)

AstraZeneca, Associate Director, Senior Patient Safety Scientist · Gaithersburg, US · AstraZeneca Careers, 2026

This November 2026 Gaithersburg posting names the Global Safety Physician and pharmacovigilance scientist. Send the discrepancy to the case’s designated physician.

Development programme coordinator interviewWho decides what the safety discrepancy means?Example

Sources

Matt Truppo, Global Head of Computational and AI Strategy R&D, Sanofi, at the time. Sanofi, “Trust Is the Real Measure of Success for AI in R&D”, Nov 9, 2026. Open the source. Checked against the published text.
Helen Merianos, SVP, Global Head of R&D Strategy & Portfolio Management, Sanofi, at the time. Sanofi, “AI Across the R&D Value Chain: Portfolio Decision-Making”, Feb 24, 2026. Open the source. Checked against the published text.
Novartis, Formulation Project Leader posting · Basel, Switzerland, at the time. Novartis Careers, “Formulation Project Leader (m/f/d)”, Oct 30, 2026. Open the source. Checked against the published text.
GSK, Company study update · issued in London, UK, at the time. GSK, “GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer”, Oct 18, 2026. Open the source. Checked against the published text.
AstraZeneca, Associate Director, Senior Patient Safety Scientist · Gaithersburg, US, at the time. AstraZeneca Careers, “Associate Director, Senior Patient Safety Scientist”, 2026. Open the source. Checked against the published text.

Last reviewed Nov 11, 2026